A contingent of 40 House Democrats has signed a letter calling on the Trump administration to avoid issuing any exclusive licenses to drug companies that end up developing vaccines or any other pharmaceuticals for the Wuhan coronavirus (CoVid-19).
Dated February 20, the letter urges President Donald Trump to ensure that all taxpayer-funded treatment protocols remain in a type of public domain, or at least be distributed among multiple drug companies to ensure fair competition and low prices in the public interest.
Issuing exclusive licenses, they further warn, “could result in an expensive medicine that is inaccessible, wasting public resources and putting public health at risk in the United States and around the globe.”
“We should not grant any manufacturer a blank check to monopolize a coronavirus vaccine or treatment developed with public, taxpayer support,” they go on to explain in the letter.
Should the Department of Health and Human Services (HHS) decide to go along with the provisions of this proposal, they would in essence be ensuring that any Wuhan coronavirus (CoVid-19) drugs are kept in the public domain, particularly when it comes to pricing.
In the event that one or a handful of drug companies schemes to jack up the prices on a Wuhan coronavirus (CoVid-19) vaccine, for instance, the HHS could intervene to drive the price back down to affordable levels for everyone.
Such an intervention “is particularly critical for vaccines, which are most effective when the vast majority of the public is immunized,” the letter goes on to contend, making a valid point that highlights the hypocrisy of Big Pharma’s longstanding vaccine monopoly that makes it cost-prohibitive for many lower-income people to achieve “herd” immunity.
Listen below as Mike Adams, the Health Ranger, shares advice about how to protect yourself against the coming coronavirus wave in the United States:
While we’re obviously not on board with the vaccine agenda, these House Democrats bring up some exceptionally valid points about the Big Pharma drug racket, and how Trump, in order to stay true to his campaign promises, owes it to the American people to break up this monopoly once and for all.
Especially when it comes to emergency medicine, Big Pharma can’t be allowed to siphon the taxpayer coffers simply to pad its own patent portfolio. If taxpayer money is going to be used to develop synthetic medicines, especially during a global emergency, then the end product needs to be readily available at affordable prices to the populace that paid for it.
As it turns out, the National Institutes of Health (NIH) has already spent a whopping $700 million in taxpayer dollars on coronavirus research, which began as far back as 2002 following the infamous SARS (severe acute respiratory syndrome) outbreak of that same year.
The pharmaceutical industry is currently running six different coronavirus clinical trials, and various nonprofit and public institutions, funded by taxpayers, are supporting all of them, reports indicate. These same taxpayer-funded entities are also supporting upwards of two-thirds of the current vaccine and drug efforts aimed at the Wuhan coronavirus (CoVid-19).
If the Trump administration fails to take aggressive action against a Wuhan coronavirus (CoVid-19) drug and vaccine monopoly, then many Americans, as well as poorer people elsewhere in the world, will not be afforded the same protection against the disease as their wealthier counterparts.
“If MY money pays for it, it is MY drug,” wrote one insightful commenter at The Epoch Times. “I (the taxpayer) am the investor. We are paying these researchers to do a JOB, not to take our money and then screw us over.”
You can hear more podcasts each day at the official Brighteon.com H.R. Report channel.
More coronavirus news is also available at the new-and-improved Pandemic.news.
Sources for this article include: